Inventor · disambiguated record
Demetrios Kalaitzidis
Also filed as: KALAITZIDIS DEMETRIOS
23 granted patents·13 pending applications·90 citations·filing 2018–2025
95Inventor score
Files withCRISPR THERAPEUTICS AG36
Top patents by PatentIndex Score
36 records- 0198US11191783B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 7, 2021·6 cites·19 claims
- 0298US11166985B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Nov 9, 2021·10 cites·14 claims
- 0398US11135247B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Oct 5, 2021·6 cites·20 claims
- 0498US11071755B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·7 cites·24 claims
- 0598US11013767B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 25, 2021·5 cites·13 claims
- 0698US10736919B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 11, 2020·13 cites·11 claims
- 0797US11207351B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 0897US10881689B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Jan 5, 2021·7 cites·29 claims
- 0997US10857184B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Dec 8, 2020·9 cites·7 claims
- 1097US10729725B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 4, 2020·7 cites·29 claims
- 1195US11298378B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Apr 12, 2022·2 cites·29 claims
- 1295US11202802B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 21, 2021·2 cites·19 claims
- 1394US11254912B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 22, 2022·5 cites·14 claims
- 1493US11497773B2Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Nov 15, 2022·2 cites·20 claims
- 1593US11471491B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 18, 2022·1 cites·18 claims
- 1692US11649438B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted May 16, 2023·2 cites·18 claims
- 1789US11679130B2Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Jun 20, 2023·1 cites·29 claims
- 1889US11622977B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2018·Granted Apr 11, 2023·1 cites·25 claims
- 1988US2023302053A1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2084US11389481B2Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19CRISPR THERAPEUTICS AG·Filed 2021·Granted Jul 19, 2022·1 cites·20 claims
- 2182US11857574B2Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2022·Granted Jan 2, 2024·0 cites·21 claims
- 2277US11679131B2Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Jun 20, 2023·0 cites·29 claims
- 2374US2022090012A1Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 2474US2025179146A1Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 2573US12227763B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2019·Granted Feb 18, 2025·0 cites·9 claims
- 2668US2025257320A1Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 2762US2023303713A1Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereofCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2858US2023046228A1Methods for manufacturing genetically engineered car-t cellsCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2956US2022249558A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 3055US12344656B2Genetically engineered T cells having improved persistence in cultureCRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 1, 2025·0 cites·13 claims
- 3155US2022226375A1Anti-cd33 immune cell cancer therapyCRISPR THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 3255US2021363212A1Genetically engineered car t cells that secret interleukin-12 and therapeutic uses thereofCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 3354US2022118019A1Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 3453US2021139850A1Manufacturing process for making t cells expressing chimeric antigen receptorsCRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 3552US2022023344A1Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19CRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 3650US2021139935A1Methods of manufacturing car-t cellsCRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →